-transparent.png){kind=logo}
Several pharmacologic studies of itraconazole, an orally active antifungal triazole, were conducted in humans and animals. In dogs and rats, no significant toxic effects were seen at doses of up to 40 mg/kg. Endocrinologic studies demonstrated that itraconazole, unlike ketoconazole, does not significantly affect human testicular and adrenal steroidogenesis. Pharmacokinetic studies indicated that itraconazole has a high tissue affinity and a longer half-life than ketoconazole. These pharmacologic observations suggest that itraconazole has a broader spectrum of activity than ketoconazole and a lower potential for producing adverse effects.
Related Publications
H Van Cauteren, and
J Heykants, and
R De Coster, and
G Cauwenbergh
May 1980,
Urology,
H Van Cauteren, and
J Heykants, and
R De Coster, and
G Cauwenbergh
April 1980,
International journal of radiation oncology, biology, physics,
H Van Cauteren, and
J Heykants, and
R De Coster, and
G Cauwenbergh
October 2003,
The Journal of nutrition,
H Van Cauteren, and
J Heykants, and
R De Coster, and
G Cauwenbergh
January 1994,
Contributions to nephrology,
H Van Cauteren, and
J Heykants, and
R De Coster, and
G Cauwenbergh
June 1950,
The Journal of clinical investigation,
H Van Cauteren, and
J Heykants, and
R De Coster, and
G Cauwenbergh
January 1978,
Verhandlungen der Deutschen Gesellschaft fur Rheumatologie,
H Van Cauteren, and
J Heykants, and
R De Coster, and
G Cauwenbergh
April 1960,
Minerva medica,
H Van Cauteren, and
J Heykants, and
R De Coster, and
G Cauwenbergh
January 1984,
Progress in clinical and biological research,
H Van Cauteren, and
J Heykants, and
R De Coster, and
G Cauwenbergh
February 1977,
Nature,
H Van Cauteren, and
J Heykants, and
R De Coster, and
G Cauwenbergh
June 2017,
Veterinary sciences,
